Yuan Meng

发表

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events

Ying Han, Yang Wang, X. Ren, 2021, Cancer biology & medicine.

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Xiang Xu, Ying Han, Yang Wang, 2022, Clinical lung cancer.

Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer

L. Liu, F. Wei, Wenwen Yu, 2022, Cancer Gene Therapy.

Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity

Y. Modis, M. Kosinski, B. Carragher, 2012, Virology Journal.

385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

J. Berlin, A. Adjei, P. Swiecicki, 2020 .

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results

B. Jiang, Jianxiang Wang, Yanni Zhang, 2020 .

Abstract 1871: A differentiated CD73 blocking antibody with a unique intra-dimer binding mechanism for cancer immunotherapy

T. Guo, Zhengyi Wang, Yanni Zhang, 2021, Immunology.

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

C. Theuer, A. Trigeiro, F. Robert, 2021 .

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

P. Song, A. Mehta, A. Gopal, 2021, Blood.